PMID: 9416986Jan 7, 1998Paper

Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes

Journal of Human Hypertension
R FogariC Vertommen

Abstract

The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and <116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine and standing BP was measured, 24-h urinary C-peptide, HbA1c, plasma glucose and lipid levels were evaluated and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diastolic BP values. Neither beta-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, whole body glucose utilization, HbA1c and 24-h urinary C-peptide excretion. No significant changes in...Continue Reading

Citations

Aug 10, 2007·Current Hypertension Reports·Michala E Pedersen, John R Cockcroft
Mar 19, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jatin NandaniaMohsin Vohra
Dec 4, 2003·Pharmacology & Therapeutics·Noboru Toda
Aug 2, 2007·American Journal of Therapeutics·Zafar H IsrailiManuel Velasco
May 30, 2009·Vascular Health and Risk Management·Enrico Agabiti-RoseiDamiano Rizzoni
Dec 15, 2007·Vascular Health and Risk Management·Angie Veverka, Jennifer L Salinas
Jan 6, 2011·Current Atherosclerosis Reports·Alberto Ranieri De Caterina, Antonio Maria Leone
Jan 30, 2016·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Ichiro TakumiAkio Morita
Jul 17, 2010·The American Journal of Medicine·Addison A Taylor, George L Bakris
Apr 28, 2009·Clinical Therapeutics·Judy W M Cheng
May 21, 2016·Sleep Medicine·Mitchell G Miglis
Jun 11, 2003·Journal of Clinical Pharmacy and Therapeutics·S L NuttallM J Kendall
Dec 18, 2007·Journal of Clinical Pharmacology·L Michael Prisant
Apr 5, 2013·The Journal of Clinical Hypertension·Prakash DeedwaniaLillian Brener
May 11, 2010·The American Journal of Cardiology·Alberto Ranieri De Caterina, Antonio Maria Leone
Jul 31, 2007·Expert Opinion on Pharmacotherapy·Rudolf A de BoerDirk J van Veldhuisen
Apr 23, 2004·Expert Opinion on Pharmacotherapy·John Cockcroft
Oct 4, 2015·Sleep Medicine·Vittobai Rashika Rangaraj, Kristen L Knutson
Jun 7, 2011·Metabolism: Clinical and Experimental·Camila ManriqueJames R Sowers
Nov 23, 2005·Current Problems in Cardiology·Robert WolkVirend K Somers
Jul 11, 2006·The Annals of Pharmacotherapy·Angie VeverkaJamie L Jolly
Jun 27, 2017·Journal of Hypertension·Lawrence H KwonClive Rosendorff
Dec 5, 2006·Journal of Hypertension·Pantelis A Sarafidis, George L Bakris
Feb 8, 2018·Terapevticheskiĭ arkhiv·A V BudnevskyYa S Shkatova
May 21, 2009·Journal of Cardiovascular Pharmacology·George Bakris
Mar 12, 2017·Current Hypertension Reports·Maria MarketouPanos Vardas
Jan 29, 2002·Journal of Cardiovascular Pharmacology·A C Pessina
Apr 2, 2014·The Annals of Pharmacotherapy·Toni L Ripley, Joseph J Saseen
Jan 16, 2021·American Journal of Hypertension·Paolo Palatini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.